Avidity Biosciences Inc
NASDAQ:RNA
Intrinsic Value
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). [ Read More ]
The intrinsic value of one RNA stock under the Base Case scenario is 8.57 USD. Compared to the current market price of 23.83 USD, Avidity Biosciences Inc is Overvalued by 64%.
Valuation Backtest
Avidity Biosciences Inc
Run backtest to discover the historical profit from buying and selling RNA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Avidity Biosciences Inc
Current Assets | 611.3m |
Cash & Short-Term Investments | 595.4m |
Receivables | 1.1m |
Other Current Assets | 14.9m |
Non-Current Assets | 17.2m |
PP&E | 16.7m |
Other Non-Current Assets | 596k |
Current Liabilities | 80.7m |
Accounts Payable | 8.8m |
Accrued Liabilities | 43.5m |
Other Current Liabilities | 28.4m |
Non-Current Liabilities | 47.1m |
Other Non-Current Liabilities | 47.1m |
Earnings Waterfall
Avidity Biosciences Inc
Revenue
|
9.6m
USD
|
Operating Expenses
|
-245.2m
USD
|
Operating Income
|
-235.6m
USD
|
Other Expenses
|
23.4m
USD
|
Net Income
|
-212.2m
USD
|
Free Cash Flow Analysis
Avidity Biosciences Inc
RNA Profitability Score
Profitability Due Diligence
Avidity Biosciences Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Avidity Biosciences Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
RNA Solvency Score
Solvency Due Diligence
Avidity Biosciences Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Avidity Biosciences Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RNA Price Targets Summary
Avidity Biosciences Inc
According to Wall Street analysts, the average 1-year price target for RNA is 47.65 USD with a low forecast of 33.33 USD and a high forecast of 74.55 USD.
Ownership
RNA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RNA Price
Avidity Biosciences Inc
Average Annual Return | -10.7% |
Standard Deviation of Annual Returns | 4.1% |
Max Drawdown | -86% |
Market Capitalization | 1.9B USD |
Shares Outstanding | 79 719 504 |
Percentage of Shares Shorted | 12.66% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). The company is headquartered in San Diego, California and currently employs 125 full-time employees. The company went IPO on 2020-06-12. The firm utilizes its AOC platform to design, engineer and develop therapeutics, which combine specificity of monoclonal antibodies (mAbs), with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with such therapeutics. Its lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1 (DM1) a rare monogenic muscle disease. The Company’s advancing and expanding pipeline also includes AOC 1044, the lead of three programs for the treatment of Duchenne Muscular Dystrophy (DMD), and AOC 1020, designed to treat facioscapulohumeral muscular dystrophy (FSHD). AOC 1020 consists of its mAb, which is designed to bind to TfR1 conjugated with a siRNA targeted to DUX4 mRNA to be administered as an intravenous infusion.
Contact
IPO
Employees
Officers
The intrinsic value of one RNA stock under the Base Case scenario is 8.57 USD.
Compared to the current market price of 23.83 USD, Avidity Biosciences Inc is Overvalued by 64%.